Emerging drugs for the treatment of alopecia areata.
Expert Opin Emerg Drugs
; 27(4): 379-387, 2022 12.
Article
en En
| MEDLINE
| ID: mdl-36408593
ABSTRACT
INTRODUCTION:
Alopecia Areata (AA) is the second most common non-scarring hair loss disorder, with a prevalence of 1 in 1000 and a lifetime incidence of 2% worldwide. Data from a recent American study shows that from 68,121 patients with the diagnosis of AA, 37,995 (55.8%) were prescribed treatment for AA within a year of diagnosis, however there are still no therapies able to induce permanent remission, or treatments that guarantee hair regrowth/remissions in 100% of cases, especially in longstanding/severe AA. Recently, oral baricitinib has been approved for AA, being the first drug approved for this specific indication. AREAS COVERED The current review will provide a summary of current pharmacological approaches and novel therapeutics in development. EXPERT OPINION New and very effective drugs have become available for the treatment of severe AA, and many others are expected soon. However, even new, effective treatments are not effective in all patients and recurrence rates after treatment interruption are high. AA is a systemic disease with important impact on quality of life and should not be considered just as an aesthetic problem. Treatment of the disease should take in account and possibly also address treatment of comorbidities.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Alopecia Areata
/
Inhibidores de las Cinasas Janus
Tipo de estudio:
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Expert Opin Emerg Drugs
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos